InNexus Announces Achieving Business Milestone in Development of Intracellular SuperAntibody(TM) Therapeutics
Commenting on the announcement, Dr. A. Charles Morgan, President of InNexus, said: "The antibody transfer marks an early and critical milestone in the development of intracellular SuperAntibody(TM) therapeutics. Utilizing our TransMAb(TM) technology platform, the newly enhanced TransMab antibodies will be able to enter inside cells to either turn on or turn off the apoptotic process, leading to the creation of new, useful and never before seen medications in areas as stroke and cancer."
Garth Likes, Vice President of Business Development added: "Using our TransMAb(TM) technology platform, we are able to regulate cellular functions and believe it represents a new paradigm in the use of antibodies and SuperAntibodies(TM) for the development of novel therapeutics and diagnostics."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous